Sign in

    Avi Nova

    Research Analyst at Morgan Stanley

    Avi Nova is an Equity Research Analyst at Morgan Stanley, focusing on the coverage of key players in the technology and internet sectors, including companies like Meta Platforms, Alphabet, and Amazon. Known for his in-depth analysis and actionable investment recommendations, he has garnered recognition on industry platforms for maintaining strong success rates and generating above-average returns for investors. Avi began his finance career after graduating from a top-tier business school, gaining early experience at boutique investment firms before joining Morgan Stanley in 2018. He holds several FINRA securities licenses and is recognized for his data-driven approach to equity research and commitment to professional excellence.

    Avi Nova's questions to IONIS PHARMACEUTICALS (IONS) leadership

    Avi Nova's questions to IONIS PHARMACEUTICALS (IONS) leadership • Q3 2024

    Question

    Speaking for Mike Ulz, Avi Nova asked about the olezarsen launch in FCS, inquiring about the number of patients identified and Ionis's confidence in securing market share before a competitor enters. He also asked how quickly patients in early access programs could be transitioned to the commercial drug.

    Answer

    CEO Brett Monia stated that the sales and medical affairs teams are actively identifying patients and that the company's 9+ month head start is a key advantage for securing a bolus of patients at launch. He and Chief Global Product Strategy Officer Kyle Jenne added that a rapid transition from early access to commercial drug is planned post-approval via a dedicated patient support program, initially for U.S. patients.

    Ask Fintool Equity Research AI